-
Eddie Li to join Novo Nordisk as VP regulatory affairs
PRINCETON, N.J. — Novo Nordisk has appointed a new VP regulatory affairs.
Effective Sept. 12, Eddie Li will lead the drug maker's U.S. regulatory team and maintain relationships with individuals and agencies outside of Novo Nordisk that play a role in the Food and Drug Administration's review and approval process, the company said.
Li will report to Anne Philips, corporate VP clinical development, medical and regulatory affairs for North America.
-
Bristol-Myers Squibb completes Amira acquisition
NEW YORK — Bristol-Myers Squibb has completed its previously announced acquisition of another drug maker.
Bristol said it has completed the acquisition of small-molecule pharmaceutical company Amira Pharmaceuticals, based in San Diego, for $325 million. Amira's portfolio focuses on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
The transaction was originally announced on July 21.